JP2013507453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507453A5 JP2013507453A5 JP2012534327A JP2012534327A JP2013507453A5 JP 2013507453 A5 JP2013507453 A5 JP 2013507453A5 JP 2012534327 A JP2012534327 A JP 2012534327A JP 2012534327 A JP2012534327 A JP 2012534327A JP 2013507453 A5 JP2013507453 A5 JP 2013507453A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- tautomer
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000003471 mutagenic agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 2
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25093609P | 2009-10-13 | 2009-10-13 | |
| US61/250,936 | 2009-10-13 | ||
| PCT/US2010/052514 WO2011047055A2 (en) | 2009-10-13 | 2010-10-13 | Novel mek inhibitors, useful in the treatment of diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507453A JP2013507453A (ja) | 2013-03-04 |
| JP2013507453A5 true JP2013507453A5 (cg-RX-API-DMAC7.html) | 2013-11-28 |
| JP5892612B2 JP5892612B2 (ja) | 2016-03-23 |
Family
ID=43876849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534327A Active JP5892612B2 (ja) | 2009-10-13 | 2010-10-13 | 疾患の処置に有用な新規のｍｅｋ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9034861B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2488507B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5892612B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20120094165A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102666512B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010306830C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012008599A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2814617C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2534358T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011047055A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| CA3072856A1 (en) | 2017-08-23 | 2019-02-28 | Cell Receptor AG | Combination of a mapk/erk pathway inhibitor and a glycosaminoglycan for the treatment of cancer |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4263501A1 (en) * | 2020-12-16 | 2023-10-25 | ABM Therapeutics Corporation | Kinase inhibitors and uses thereof |
| JP2024521788A (ja) | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス， インコーポレイテッド | 併用療法 |
| CN118973580A (zh) | 2022-04-08 | 2024-11-15 | 米拉蒂治疗股份有限公司 | 包含sos1抑制剂和mek抑制剂的组合疗法 |
| EP4788839A1 (en) | 2023-10-03 | 2026-08-12 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| IL330382A (en) | 2024-01-05 | 2026-08-01 | Pasithea Therapeutics Corp | Stereoisomers of 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazepine-3,1'-cyclopropane] 2,2-dioxide, as well as compositions containing them and methods of using them |
| IL330371A (en) | 2024-01-05 | 2026-08-01 | Pasithea Therapeutics Corp | Solid forms containing (5R,6S)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazepine-3,1'-cyclopropane] 2,2-dioxide, as well as compositions containing the same and methods of using the same |
| WO2026112507A1 (en) | 2024-11-22 | 2026-05-28 | Pasithea Therapeutics Corp. | Tablet formulations and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| EP0922030A1 (en) | 1996-08-23 | 1999-06-16 | Pfizer Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| US6077864A (en) | 1997-01-06 | 2000-06-20 | Pfizer Inc. | Cyclic sulfone derivatives |
| HUP0000852A2 (hu) | 1997-02-03 | 2001-05-28 | Pfizer Products Inc. | Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| NZ336836A (en) | 1997-02-11 | 2001-02-23 | Pfizer | Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments |
| TR200000368T2 (tr) | 1997-08-08 | 2000-07-21 | Pfizer Products Inc. | Ariloksiariarilsülfonilamino hidroksamik asit türevleri. |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
| GB0131034D0 (en) * | 2001-12-28 | 2002-02-13 | Pharmacia & Upjohn Spa | Benzocyclodecane derivatives with antitumor activity |
| BR0307060A (pt) | 2002-01-23 | 2004-10-26 | Warner Lambert Co | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| MX2008002114A (es) * | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| CN101495118B (zh) | 2005-07-21 | 2012-09-05 | 阿迪亚生命科学公司 | Mek的n-(芳基氨基)磺酰胺抑制剂 |
| US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
| AU2007237901B2 (en) | 2006-04-18 | 2012-07-05 | Ardea Biosciences, Inc. | Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors |
| ES2547303T3 (es) | 2007-01-19 | 2015-10-05 | Ardea Biosciences, Inc. | Inhibidores de MEK |
| CN103479604B (zh) | 2007-07-30 | 2016-08-10 | 阿迪生物科学公司 | 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法 |
| CA2694646C (en) | 2007-07-30 | 2017-09-05 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| WO2009049642A1 (en) | 2007-10-16 | 2009-04-23 | Pharmathen S.A. | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof |
| US8044240B2 (en) | 2008-03-06 | 2011-10-25 | Ardea Biosciences Inc. | Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof |
| CN102131771A (zh) | 2008-04-14 | 2011-07-20 | 阿迪生物科学公司 | 组合物及其制备和使用方法 |
| CN102134218A (zh) | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
-
2010
- 2010-10-13 CA CA2814617A patent/CA2814617C/en active Active
- 2010-10-13 KR KR1020127012271A patent/KR20120094165A/ko not_active Ceased
- 2010-10-13 CN CN201080053278.5A patent/CN102666512B/zh active Active
- 2010-10-13 JP JP2012534327A patent/JP5892612B2/ja active Active
- 2010-10-13 BR BR112012008599A patent/BR112012008599A2/pt not_active IP Right Cessation
- 2010-10-13 EP EP10824026.8A patent/EP2488507B1/en active Active
- 2010-10-13 WO PCT/US2010/052514 patent/WO2011047055A2/en not_active Ceased
- 2010-10-13 ES ES10824026.8T patent/ES2534358T3/es active Active
- 2010-10-13 AU AU2010306830A patent/AU2010306830C1/en active Active
- 2010-10-13 US US13/501,442 patent/US9034861B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11220477B2 (en) | Modulators of the eIF2alpha pathway | |
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| US10864196B2 (en) | Modulators of the integrated stress pathway | |
| JP6342805B2 (ja) | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 | |
| US10836725B2 (en) | Modulators of the integrated stress pathway | |
| US20250115563A1 (en) | Modulators of the integrated stress pathway | |
| JP2015520753A5 (cg-RX-API-DMAC7.html) | ||
| ES2758923T3 (es) | Tratamiento de esteatohepatitis no alcohólica | |
| RS65214B1 (sr) | Modulatori integrisanog puta stresa | |
| US12551482B2 (en) | Aurora kinase inhibitors | |
| EA019064B1 (ru) | Способы лечения рака с применением хинаксолинового ингибитора pi3k-альфа | |
| KR20160006668A (ko) | 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물 | |
| EA020022B1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа | |
| US11612604B2 (en) | Methods of treating cancer with PLK4 inhibitors | |
| CA2982890C (en) | Plk4 inhibitors | |
| EP3102202A1 (en) | Neurodegenerative therapies | |
| WO2024039689A1 (en) | Heterocycle rbm39 modulators | |
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| US11840523B2 (en) | IRE1α inhibitors and uses thereof | |
| JP2023525758A5 (cg-RX-API-DMAC7.html) | ||
| JP2020536890A (ja) | 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ | |
| CN104622874B (zh) | Ccr4拮抗剂在抑制癌生长及转移中的应用 | |
| TR201908031T4 (tr) | İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu. | |
| RU2007131105A (ru) | Производные пиразола, предназначенные для ингибирования циклинзависимых киназ (cdk) и киназ гликогенсинтазы (gsk) |